EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons

Alisa Gisina iD, Yan Kim iD, Konstantin Yarygin iD, Alexey Lupatov

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms242417398 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Alisa Gisina und 3 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cell Biology, V. N. Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia. Hauptthemen laut MEDLINE: Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 199 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Higher Education of the Russian Federation, Ministry of Education and Science of the Russian Federation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The CD133 cell membrane glycoprotein, also termed prominin-1, is expressed on some of the tumor cells of both solid and blood malignancies. The CD133-positive tumor cells were shown to exhibit higher proliferative activity, greater chemo- and radioresistance, and enhanced tumorigenicity compared to their CD133-negative counterparts. For this reason, CD133 is regarded as a potential prognostic biomarker in oncology. The CD133-positive cells are related to the cancer stem cell subpopulation in many types of cancer. Recent studies demonstrated the involvement of CD133 in the regulation of proliferation, autophagy, and apoptosis in cancer cells. There is also evidence of its participation in the epithelial–mesenchymal transition associated with tumor progression. For a number of malignant tumor types, high CD133 expression is associated with poor prognosis, and the prognostic significance of CD133 has been confirmed in a number of meta-analyses. However, some published papers suggest that CD133 has no prognostic significance or even demonstrate a certain correlation between high CD133 levels and a positive prognosis. This review summarizes and discusses the existing evidence for and against the prognostic significance of CD133 in cancer. We also consider possible reasons for conflicting findings from the studies of the clinical significance of CD133.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsHumansPrognosisApoptosisBiomarkersAC133 AntigenNeoplastic Stem CellsBiomarkers, Tumor

Stichwörter der Autor:innen

CD133cancer biomarkercancer prognosiscancer stem cellsprominin-1

Substanzen

BiomarkersAC133 AntigenBiomarkers, Tumor

Autor:innen und Institutionen

  • Laboratory of Cell Biology, V. N. Orekhovich Institute of Biomedical Chemistry, 119121 Moscow, Russia.

ORCID-Profile: Alisa Gisina, Yan Kim, Konstantin Yarygin

Förderung

  • Ministry of Science and Higher Education of the Russian Federation
  • Ministry of Education and Science of the Russian Federation

Zitieren

APA

Gisina, A., Kim, Y., Yarygin, K., & Lupatov, A. (2023). Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242417398

Vancouver

Gisina A, Kim Y, Yarygin K, Lupatov A. Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242417398

BibTeX
@article{Gisina2023,
  author = {Gisina, Alisa and Kim, Yan and Yarygin, Konstantin and Lupatov, Alexey},
  title = {Can CD133 Be Regarded as a Prognostic Biomarker in Oncology: Pros and Cons},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms242417398}
}
Kostenlos starten →